Canopy Growth Corporation
NASDAQ:CGCDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $212.31M
- Beta
- 0.78
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.76
Volume 3.44M
Average 9.97M
CGC Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Canopy Growth CorporationNASDAQ: CGC
Net Income · Q4 FY2025 · quarter ended Mar 2026
Net income declines year over year
Q4 FY2025 net income of CA$157.12M (cash outflow) fell 29.1% year over year, ahead of the -52.6% change in trailing-twelve-month net income. Sequentially, it rose 82.8% from the prior quarter. Over 3 fiscal years it compounded at -50.8% a year.
Context
- Net income amounted to 75.8% of revenue in FY2025, down 148.8 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -CA$47.11M (-87.1%) for the fiscal year ending Mar 2027, a slowdown from the -39.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -CA$157.12M+82.8% QoQ
- Last fiscal yearMar 2026
- -CA$366.64M-39.3% YoY
- LTMMar 2026
- -CA$286.21M-52.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -29.1% | -57.7% | -28.6 pp |
| 1 year | -39.3% | -87.1% | -47.8 pp |
| 3-year CAGR | -50.8% | -58.9% | -8.1 pp |
| 5-year CAGR | -46.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
CAD · from the cash flow
- Latest · FY2025
- (366.64M) CAD
- Year-over-year change
- +39.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2026-03-31 | (366.64M) | +39.3% |
| FY2024 | 2025-03-31 | (604.14M) | -24.9% |
| FY2023 | 2024-03-31 | (483.68M) | +84.3% |
| FY2022 | 2023-03-31 | (3.08B) | -1089.8% |
| FY2021 | 2022-03-31 | (258.91M) | — |
Net Income vs competitors
How CGC compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -52.6% is the 7th highest of 9, against a peer median of -26.3%.
- Net income amounts to 91.6% of revenue for CGC, versus a peer median of 61.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$286.21M CAD | -52.6% | -50.8% | 91.6% | |
| LTM Mar 2026 | $246.41M USD | -26.3% | +14.4% | 794858.1% | |
| LTM Mar 2026 | $182.83M USD | -71.5% | +107.7% | 76.7% | |
| LTM Mar 2026 | $175.43M USD | +38.4% | +46.9% | — | |
| LTM Mar 2026 | $165.86M USD | +628.0% | -48.4% | 45.9% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $89.93M USD | +26.6% | +26.6% | 871.8% |
| LTM Mar 2026 | $69.66M USD | -46.5% | -9.3% | 832.6% | |
| LTM Mar 2026 | CA$58.58M CAD | -507.7% | -39.5% | 18.8% | |
| LTM Mar 2026 | $34.09M USD | — | -30.8% | 25.2% | |
| LTM Mar 2026 | $17.17M USD | -26.3% | -28.6% | 41.1% | |
| Peer median (excluding CGC) | — | -26.3% | -9.3% | 61.3% | |
Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Mar 2022 | FY2022 Mar 2023 | FY2023 Mar 2024 | FY2024 Mar 2025 | FY2025 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | (258.91M) | (3.08B) | (483.68M) | (604.14M) | (366.64M) |
| Depreciation & Amortization | 110.94M | 80.03M | 53.18M | 43.12M | 50.86M |
| Deferred Income Tax | (8.95M) | (5.73M) | 12.33M | 7.14M | 0 |
| Stock-Based Compensation | 46.69M | 25.32M | 14.18M | (4.21M) | 5.95M |
| Change in Working Capital | 205M | 58.97M | 3.97M | (31.97M) | 20.68M |
| Accounts Receivables | 16.15M | 6.24M | (3.75M) | (4.49M) | 25.69M |
| Inventory | 204.22M | 68.44M | 1.03M | (17.72M) | 3.71M |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (15.37M) | (15.71M) | 6.68M | (9.77M) | (8.72M) |
| Other Non-Cash Items | (640.58M) | 2.36B | 118.08M | 424.3M | 200.17M |
| Operating Cash Flow | (545.81M) | (557.55M) | (281.95M) | (165.75M) | (88.98M) |
| Capital Expenditures | (48.11M) | (10.45M) | (4M) | (11.28M) | (7.44M) |
| Acquisitions (Net) | 103.2M | 14.93M | (955K) | (6.97M) | 0 |
| Purchases of Investments | (379.41M) | (67.15M) | (347K) | (95.34M) | 0 |
| Sales of Investments | 546.01M | 502.59M | 78.55M | 16.43M | 26.5M |
| Other Investing Activities | (2.3M) | (7.88M) | 167.79M | 48.9M | (48.83M) |
| Investing Cash Flow | 230.82M | 433.38M | 241.59M | (47.79M) | (29.77M) |
| Debt Repayment | (50.76M) | 16.98M | (509.78M) | (220.78M) | (24.62M) |
| Common Stock Issued | 2.7M | 1.05M | 81.06M | 385.39M | 374.17M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.53M | (37.72M) | (36.34M) | (15.96M) | 114.02M |
| Financing Cash Flow | (45.53M) | (19.69M) | (465.06M) | 148.66M | 463.57M |
| Effect of Forex Changes | (18.12M) | 44.86M | (1.29M) | 8.39M | 5.05M |
| Net Change in Cash | (378.65M) | (99M) | (506.71M) | (56.49M) | 349.86M |
| Free Cash Flow | (593.92M) | (568M) | (285.95M) | (177.03M) | (96.42M) |
Canopy Growth Corporation
NASDAQ:CGC
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.